The PI3K/Akt pathway is activated in response to various microenvironmental stimuli that regulate the survival and proliferation of chronic lymphocytic leukemia (CLL) B-cells, including triggering of the B-cell receptor (BCR). Although this pathway is frequently targeted in cancer, no significant alterations have yet been identified in CLL. We now show that the phosphatase PH domain leucin-rich repeat protein phosphatase (PHLPP1), a recently identified tumor suppressor and negative regulator of the Akt kinase, is absent or expressed at substantially reduced levels in CLL B-cells. To determine what the consequences of PHLPP1 loss on BCR signaling are, we downregulated or re-expressed PHLPP1 in lymphoma cell lines and primary CLL B-cells, respectively. Downregulation of PHLPP1 increased BCR-induced phosphorylation and activation of the Akt, GSK3 and ERK kinases, whereas re-expression had the opposite effect. Importantly, re-expression of PHLPP1 in primary CLL cells prevented upregulation of Mcl-1 and inhibited the increase in leukemic cell viability induced by sustained BCR engagement. Enforced expression of PHLPP1 also affected the response to other microenvironmental stimuli, particularly in terms of ERK phosphorylation. Collectively, these data show that CLL cells lack an important negative regulator of the Akt and ERK pathways, which could confer them a growth advantage by facilitating the propagation of crucial microenvironment-derived stimuli.
Introduction
The proliferation and survival of chronic lymphocytic leukemia (CLL) B-cells is regulated by intracellular signaling pathways that are activated by various stimuli from the microenvironment. Among these, antigenic stimuli that are propagated through the B-cell receptor (BCR) are considered to have a major role in the initiation, maintenance and evolution of the malignant clone. 1, 2 A key signaling molecule downstream of the BCR in CLL B-cells is the Akt kinase, sustained activation of which induces changes in the expression of several cell cycle and apoptosisregulatory proteins, including cyclin D3, Mcl-1, Bcl-xL and XIAP. [3] [4] [5] This kinase is also activated in response to many other microenvironmental stimuli that increase leukemic cell survival or induce proliferation, including CXCL12, CD40 ligand, IL-4, CpG oligonucleotides, lysophosphatidic acid, high-density lipoprotein particles and contact with bone marrow stromal cells. [6] [7] [8] [9] [10] [11] [12] [13] In addition, increased basal Akt activity has been reported in some studies, suggesting that constitutive Akt signaling may contribute to the increased survival of the malignant lymphocytes. In line with this possibility, specific inhibition or downregulation of Akt has been shown to induce apoptosis in freshly isolated CLL cells. 14, 15 Akt is activated following its recruitment to the plasma membrane, where it binds phosphorylated phosphoinositol substrates (phosphatidylinositol 3,4,5-trisphosphate) that are generated by PI3K in response to growth-promoting external stimuli. Subsequently, Akt is phosphorylated on Thr308 in the activation loop and Ser473 in the C-terminal hydrophobic motif by PDK1 and the mTORC2 complex, respectively. 16, 17 This dual phosphorylation causes full activation of Akt and allows it to phosphorylate downstream signaling molecules. The activity of Akt is negatively regulated by the phosphatases PTEN and SHIP, which dephosphorylate phosphatidylinositol 3,4,5-trisphosphate. In addition, a novel family of Ser/Thr phosphatases named PHLPP (PH domain leucin-rich repeat protein phosphatase) has recently been identified and shown to directly dephosphorylate Ser473 and terminate Akt signaling. [18] [19] [20] The PHLPP family is composed of three members: PHLPP1a, PHLPP1b (also designated SCOP) and PHLPP2. 20, 21 PHLPP1a and PHLPP1b are alternatively spliced isoforms that are encoded by the same gene. PHLPP1b differs from PHLPP1a by a 512-amino-acid N-terminal extension that contains a Ras-association domain, whereas the remaining sequence is identical. All PHLPP phosphatases have been shown to dephosphorylate Akt, although a difference in their preference for the various Akt isoforms has been reported. 20 In addition, both PHLPP1 and PHLPP2 have been shown to dephosphorylate PKCa and PKCbII, whereas PHLPP1 has also been implicated in the negative regulation of the Ras/Raf/MEK/ERK pathway. 22, 23 Recently, several lines of evidence have suggested that PHLPP1 and PHLPP2 are involved in the pathogenesis of various types of cancer. Reduced or absent expression of PHLPP1 and PHLPP2 has been reported in approximately 80% of primary colorectal cancer specimen. 24 In addition, loss of PHLPP1 has been observed in glioblastoma, breast cancer and chronic myeloid leukemia cells. 19, 25, 26 Reintroduction or overexpression of PHLPP1 in these cell types results in decreased basal or agonist-induced Akt activity, increased apoptosis and inhibition of proliferation, further suggesting that this phosphatase can function as a tumor suppressor. 19 During a recent gene expression profiling analysis, we observed that PHLPP1 mRNA is undetectable in almost 40% of the investigated CLL B-cell samples. 27 This observation, along with the important role of Akt in regulating CLL cell survival and proliferation, prompted us to investigate in more detail the expression of PHLPP1 and PHLPP2 in a large series of primary CLL B-cell samples and normal B lymphocytes. Surprisingly, we find that at the protein level PHLPP1 is either not expressed or expressed at markedly reduced amounts in all CLL samples, including cases that express substantial amounts of PHLPP1 mRNA. Reintroduction of PHLPP1 in primary CLL cells inhibited BCR-induced activation of the Akt and ERK pathways and inhibited the antiapoptotic BCR signal, suggesting that loss of PHLPP1 expression is a functionally relevant event that could contribute to the pathogenesis of CLL.
Materials and methods

CLL and normal B-cell samples
Blood samples were collected from patients who satisfied standard morphological and immunophenotypic criteria for B-cell CLL. Informed consent was obtained from all patients according to the Declaration of Helsinki and approval for the study was obtained from the institutional human research committee at the Catholic University Hospital 'A Gemelli'. Clinical and laboratory features of the studied patients are provided in Supplementary Table 1 .
Normal B-cells were obtained from tonsils (n ¼ 4) or from peripheral blood of healthy donors (n ¼ 3). Mononuclear cells were isolated from peripheral blood and tonsil samples by Ficoll gradient centrifugation. CLL and normal B-cells were purified by negative selection with anti-CD3, anti-CD14 and anti-CD16 mouse monoclonal antibodies (kindly provided by Prof. Fabio Malavasi, University of Turin, Italy) and Dynabeads coated with pan anti-mouse IgG antibody (Dynal Biotech, Oslo, Norway). The purity of the selected B-cell populations was evaluated by staining with anti-CD5 R-phycoerythrin (R-PE)-conjugated and anti-CD19 fluorescein (FITC)-conjugated antibodies (BD Biosciences, Franklin Lakes, NJ, USA), followed by flow cytometry analysis on a FACSCalibur flow cytometer (BD Biosciences). The purity of the CLL B-cell samples always exceeded 97%, the purity of the tonsillar B-cell samples ranged from 75 to 85%, whereas the purity of the B-cell samples obtained from peripheral blood ranged from 65 to 75%.
Cell lines and culture conditions
Freshly isolated CLL B-cells and the cell lines BJAB (Burkitt's lymphoma), MEC1 (CLL-derived prolymphocytic leukemia), DHL4, DHL6, DHL8, DHL10, OCI LY1, LY3, LY7, LY18, Wsu-NHL, Toledo (all diffuse large B-cell lymphomas) and B104 (unspecified B-cell lymphoma) were cultured in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine and 1 mM sodium pyruvate (Invitrogen, Carlsbad, CA, USA), at 37 1C in the presence of 5% CO 2 . NIH3T3 fibroblasts, untransfected or stably transfected with CD40 ligand (3T40L cells) (both are kind gifts of Dr Eric Eldering, Academic Medical Center, Amsterdam, The Netherlands), were cultured in IMDM supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine and 3.57 Â 10 À4 % (vol/vol) b-mercaptoethanol. CLL or lymphoma B-cells (1 Â 10 7 /ml) were stimulated with the following reagents: 10 mg/ml goat F(ab 0 ) 2 /ml 3T40L cells, as described elsewhere. 3, 9, 28 The calpain inhibitor calpeptin (13 mM) (Calbiochem-Merck, Darmstadt, Germany), the proteasome inhibitor epoxomicin (100 nM) (Alexis Biochemicals, San Diego, CA, USA) and the pancaspase inhibitor Z-VAD-fmk (100 mM) (BD Biosciences) were used as indicated.
Plasmid constructs, small interfering RNAs, mRNA preparation and nucleofection
The RNA interference experiments were performed with Control SmartPool small interfering RNAs and PHLPP1 SmartPool siRNAs that target both PHLPP1 isoforms (Dharmacon, Lafayette, CO, USA). Transfection experiments were performed with the PHLPP1a isoform because of the availability of an expression vector (pCMV6-Entry-PHLPP1a, OriGene Technologies, Inc., Rockville, MD, USA). The pCMV6-EntryPHLPP1a and the control pCDNA3 plasmid were purified with the Plasmid Maxi Kit (Qiagen, Hilden, Germany). Capped and poly(A) tailed mRNAs were prepared from the above-described vectors using the mMESSAGE mMACHINE T7 Ultra Kit and purified with the MEGAclear kit (both from Ambion, Austin, TX, USA). Nucleofection of siRNAs or mRNAs in DHL-4, BJAB, MEC1 and primary CLL B-cells was performed with the Nucleofector system (Amaxa Biosystems GmbH, Cologne, Germany) using Nucleofector Solution L or V and the C-005 and U-13 programs, respectively.
Immunoblotting analysis
Cell pellets were lysed in RIPA lysis buffer (10 mM Tris-HCl, pH 7.4, 5 mM EDTA, 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 0.1% sodium deoxycholate) containing protease and phosphatase inhibitors (Sigma-Aldrich, St Louis, MO, USA). The protein concentration of each cell lysate was determined with the RC-DC Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA). The protein samples were separated by SDS-PAGE and transferred on Immobilon-P polyvinylidene difluoride membranes. Membranes were blotted at 4 1C with the following antibodies: PHLPP1 (recognizes both the a and the b isoform), PHLPP2 (Bethyl Laboratories, Inc, Montgomery, TX, USA), SHIP, PARP, phospho-
Thr32 phospho-PKCb2
Ser660 rabbit IgG-HRP, mouse IgG HRP-linked (Cell Signaling Technology, Danvers, MA, USA), phospho-Akt Thr308 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or b-actin (Sigma-Aldrich). Immunodetection and quantification were done on a Gel Logic 2200 Imaging System (Eastman Kodak, Rochester, NY, USA), using ECL Plus enhanced-chemiluminescence detection reagents (Amersham Biosciences, Buckinghamshire, UK).
Real-time RT-PCR analysis
RNA was isolated with the Trizol reagent (Invitrogen) and reverse transcribed using random hexamers. Real-time quantitative PCR was performed on an ABI Prism 7700 instrument (Applied Biosystems, Forster City, CA, USA) using a TaqMan pre-designed PHLPP1 gene expression assay that detects both PHLPP1 isoforms (Applied Biosystems). b-Actin was used as a calibrator in these experiments. Samples were run in triplicate and relative quantification was performed with the comparative Ct method.
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Apoptosis assay 
Statistical analysis
Paired t-test or Wilcoxon's signed rank test was used as appropriate to evaluate the significance of differences in leukemic cell survival and expression of phosphorylated Akt, GSK3 and ERK. All analyses were performed with the SigmaStat 3.1 program (Systat Software, Richmond, CA, USA). P values are indicated in the figures.
Results
PHLPP1 and PHLPP2 protein levels in normal and malignant B-cells
Expression of PHLPP1 was investigated by immunoblotting in 53 purified CLL B-cell samples, 13 lymphoma cell lines and 7 purified normal B-cell samples, of which 4 were obtained from tonsils and 3 from peripheral blood of healthy donors. A 190-kDa protein, corresponding to the PHLPP1b isoform, was detected in all normal B-cell samples and in most lymphoma cell lines ( Figure 1a ). The 140-kDa PHLPP1a isoform was also detected, although at substantially lower levels, in most of these samples. Remarkably, neither PHLPP1a nor PHLPP1b was expressed at appreciable levels in any of the investigated CLL samples, with maximum levels of expression falling below 10% of the levels in normal B-cells (Figures 1a and b) . In contrast to PHLPP1, PHLPP2 was rather uniformly expressed in CLL, lymphoma and normal B-cells. SHIP, which is another important regulator of the PI3K/Akt pathway, was also expressed at similar levels in the three series of samples, with the exception of the MEC1 cell line, wherein no SHIP protein was detected. Together, these analyses demonstrated that loss of PHLPP1 expression is a specific and uniform feature of CLL cells. To investigate the reasons for the loss of PHLPP1 expression, we evaluated the levels of PHLPP1 mRNA by real-time RT-PCR in 16 CLL samples, 5 normal B-cell samples and 5 lymphoma B-cell lines. The difference in protein expression was reflected at the mRNA level in 88% of the CLL samples, suggesting that transcriptional repression is primarily responsible for the lack of PHLPP1 protein (Figure 2a) . However, in two CLL samples we detected substantial amounts of PHLPP1 mRNA, although neither of them expressed PHLPP1 at the protein level. As PHLPP1 has been reported to be rapidly turned over in certain cell types by calpain or proteasomal degradation, 29, 30 we investigated whether specific inhibitors of these degradation pathways will increase PHLPP1 protein levels in primary CLL cells. As shown in Figure 2b , incubation of primary CLL cells with the calpain inhibitor calpeptin, the proteasome inhibitor epoxomicin or the caspase inhibitor Z-VAD-fmk did not induce any changes in PHLPP1 protein expression, both in terms of endogenous PHLPP1 (left panels) as well as PHLPP1 introduced in primary CLL cells by nucleofection of in vitro-transcribed PHLPP1a mRNA (right panel). In addition, time-course experiments did not reveal any difference in PHLPP1a protein half-life between primary CLL cells and DHL4 lymphoma cells transfected with PHLPP1a mRNA (Figure 2c ), suggesting that CLL cells do not have an excessive rate of PHLPP1 protein turnover.
PHLPP1 regulates BCR-induced activation of Akt and ERK in lymphoma and CLL B cells
We next investigated whether reduced PHLPP1 expression affects Akt and ERK signaling in malignant B-lymphocytes stimulated through the BCR. Experiments were first performed with the BJAB, DHL4 and MEC1 cell lines, in which PHLPP1 was downregulated by RNA interference. A significant reduction in PHLPP1 expression was achieved in all cell lines, with levels ranging from 5 to 30% of the levels in cells transfected with control siRNA (Figure 3a) . Immunoblotting analysis of protein extracts from unstimulated cells transfected with PHLPP1 siRNA did not show any increase in Akt phosphorylation on activating Ser473 and Thr308 residues, indicating that reduced PHLPP1 expression does not affect the basal activity of Akt in these cells. However, anti-IgG or anti-IgM-induced phosphorylation of Akt, GSK3 and ERK consistently increased in PHLPP1 siRNAtransfected cells, particularly at the later time points. The increase in the amount of phosphorylated protein was highly significant for pAkt Ser473 (P ¼ 0.004) and pGSK3 (Po0.001), and to a lesser extent for pAkt Thr308 (Figure 4 ). This inhibitory effect of PHLPP1 on Akt and ERK phosphorylation was observed regardless of whether BCR crosslinking was performed with soluble or immobilized anti-IgM (Figures 4b and c, respectively) .
PHLPP1 inhibits the antiapoptotic BCR signal in CLL cells
Previous studies by our group had shown that sustained BCR engagement with immobilized anti-IgM increases the resistance of the leukemic cells to spontaneous and chemotherapyinduced apoptosis. 3 This antiapoptotic BCR signal was shown to depend on induction of the Bcl-2 family protein Mcl-1, which is post-transcriptionally regulated by the Akt kinase. 4 To determine whether expression of PHLPP1 will affect the propagation of this antiapoptotic signal, CLL B-cells from 13 patients were nucleofected with PHLPP1a mRNA, placed in culture for 3 h to allow for maximal expression of PHLPP1 protein and then stimulated for additional 20 h with immobilized anti-IgM. Annexin V/propidium iodide staining showed that the viability of anti-IgM-stimulated CLL cells transfected with PHLPP1a mRNA was significantly reduced with respect to cells transfected with control mRNA, demonstrating that PHLPP1 expression inhibits the antiapoptotic BCR signal (Figure 5a) . A mild reduction in the viability of unstimulated CLL cells transfected with PHLPP1a mRNA relative to cells transfected with control mRNA was also observed, but this difference did not reach statistical significance. 
PHLPP1 modulates the response to other microenvironmental stimuli in CLL cells
To investigate whether PHLPP1 regulates the response to other microenvironmental stimuli, we performed an additional set of experiments in which leukemic cells were nucleofected with control or PHLPP1a mRNA, and then stimulated with various agonists that have been shown to induce Akt and ERK activation in CLL cells, including TPA, CD40 ligand, CpG-ODN and SDF1a. Expression of PHLPP1 reduced the amount of phosphorylated Akt, GSK3 and ERK in CLL cells stimulated with the phorbol ester TPA; a minor reduction in the amount of phosphorylated PKCb was also observed in this experiment ( Figure 6 ). In CLL cells stimulated with CD40 ligand, CpG-ODN and SDF1a, the phospho-Akt signal was very weak or below the level of detection and therefore no effect of PHLPP1 expression was observed. However, ERK phosphorylation was clearly induced by these stimuli and inhibited by PHLPP1. Together, these data suggest that loss of PHLPP1 expression can also affect the response of CLL cells to other microenvironmental stimuli, in addition to the signal propagated through the BCR.
Discussion
Somatic mutations in various regulatory components of the PI3K/Akt pathway represent some of the most frequent genetic alterations in cancer. [31] [32] [33] [34] Interestingly, despite the fact that this pathway is considered to have a major role in regulating the survival and proliferation of the leukemic cells, no such mutations have yet been identified in CLL. [35] [36] [37] The only abnormality that has been reported so far is reduced expression of the phosphatase PTEN, which was observed in approximately 50% of the cases in one study. 38 Thus, the uniform loss of PHLPP1 expression described in our current study can be considered to be the first major alteration of the PI3K/Akt pathway in CLL, which is likely to have a role in the pathogenesis of this disease by way of facilitating the propagation of growth and survival signals from the leukemic-cell microenvironment.
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PHLPP1 regulates Akt and ERK signaling in CLL M Suljagic et al vast majority of cases. However, cases with substantial levels of PHLPP1 mRNA were observed both in the current and in a previous study by our group, suggesting that other mechanisms are also involved in repressing PHLPP1 protein expression. 27 As PHLPP1 has been shown to undergo rapid turnover in certain cell types because of calpain proteolysis or proteasomal degradation, we considered the possibility that increased calpain or proteasomal activity may be preventing PHLPP1 protein accumulation in CLL cells. 29, 30, [39] [40] [41] However, neither calpain nor proteasomal inhibitors could increase the levels of endogenous PHLPP1 or PHLPP1 introduced in CLL cells by mRNA transfection, suggesting that CLL cells do not have an excessive rate of PHLPP1 protein turnover. Therefore, other mechanisms will have to be considered in future studies to explain the absence of PHLPP1 protein in CLL cells that express normal levels of PHLPP1 mRNA, including mutations in the coding region sequence or translational repression.
PHLPP1 has been shown to inhibit both basal and agonistinduced Akt activity in several cancer cell lines. 19, 20, 24 In this study we did not observe a significant change in the basal phosphorylation of Akt and its targets GSK-3 and FoxO1/3a, neither following downregulation of PHLPP1 in lymphoma B-cell lines nor following its reintroduction in primary CLL cells. However, basal phospho-Akt levels in the investigated lymphoma cell lines and primary CLL cells were relatively low and therefore subtle differences may have remained undetected. Thus, although our data suggest that loss of PHLPP1 does not lead to increased basal Akt activity in CLL B-cells, a minor effect cannot be excluded.
In contrast to basal Akt activity, agonist-induced Akt activation was significantly affected by changes in PHLPP1 expression. Thus, downregulation of PHLPP1 in lymphoma B-cells resulted in a consistent increase in BCR-induced phosphorylation of Akt and GSK-3, which was especially evident at later time points. A similar effect was observed in terms of ERK phosphorylation. These results were further corroborated by introduction of PHLPP1a in primary CLL cells, which resulted in inhibition of anti-IgM-induced Akt and ERK phosphorylation. Importantly, introduction of PHLPP1 in CLL cells affected not only transduction of the BCR signal, but also the cellular response to BCR engagement. This was evidenced by the significantly reduced increase in the viability of anti-IgM-stimulated CLL cells transfected with PHLPP1 mRNA in comparison with cells transfected with control mRNA. In addition, PHLPP1 prevented the anti-IgM-induced increase in the expression of Mcl-1, which is an important mediator of apoptosis resistance in CLL cells.
Antigen stimulation of the BCR is considered to have a key role in the development and progression of CLL. This view is supported by several lines of evidence, including the frequent -60  30  10  -60  30  10  -60  30  10  -60  30  10  -60  30 PHLPP1 regulates Akt and ERK signaling in CLL M Suljagic et al appears quite paradoxical that the response of CLL cells to BCR engagement in vitro is rather heterogeneous and is often reduced in comparison with normal B-cells, at least in terms of proximal signaling events. 43, 44 This heterogeneity has been attributed to the altered expression of several molecules that propagate or modulate the BCR signal, such as ZAP-70, CD5, surface Ig, PKCbII, TCL1 and p66Shc. 5, [45] [46] [47] Some of these changes have been shown to attenuate BCR signal transduction (for example, CD5 expression, low levels of surface Ig, overexpression of PKCbII), whereas others apparently have an opposite effect (expression of ZAP-70, expression of TCL1, downregulation of p66Shc). The reason why CLL cells aberrantly express signaling molecules with opposing net effects on BCR signal transduction is still unclear, but one possible explanation is that these changes allow CLL cells to more delicately fine-tune the BCR signal, so that cell activation can be kept below the potentially proapoptotic level responsible for negative selection, while allowing antiapoptotic signals to be propagated and eventually amplified. In this respect, it is worth noting that CLL cells frequently express polyreactive BCRs and therefore could possibly encounter antigens with opposing effects on survival. Loss of PHLPP1 expression could be particularly beneficial in such a setting, as it would selectively increase the intensity of the antiapoptotic BCR signal by allowing for greater activation of the Akt and ERK kinases, which are important downstream mediators of CLL cell survival.
The data presented in this study also suggest that loss of PHLPP1 expression could affect signaling through other pathways that converge on the Akt and ERK kinases. The effect of PHLPP1 in modulating the response to other stimuli was particularly evident in terms of ERK phosphorylation, which was inhibited when CLL cells were stimulated with TPA, CD40 ligand, CpG-ODN and SDF1a. In terms of Akt phosphorylation, an inhibitory effect was observed only in CLL cells stimulated with TPA, whereas Akt phosphorylation was not detected or was only barely detectable when these cells were stimulated with CD40 ligand, CpG-ODN and SDF1a. The absence of Akt phosphorylation in the latter experiments can be explained by the heterogeneous response of CLL cells to these stimuli or the insufficient sensitivity of our assay to detect a response to weak Akt agonists.
A role for the Akt kinase in the pathogenesis of CLL was initially suggested by the development of CD5 þ /IgM þ B-cell leukemias in mice transgenic for the TCL1 oncogene, which is an important co-activator of Akt. 48 The leukemias in these mice are considered to be antigen-driven, 49 suggesting that TCL1 contributes to leukemogenesis by enhancing BCR-induced activation of Akt and related pathways. Based on our findings it would be expected that knockout mice with targeted disruption of the PHLPP1 gene should develop a similar disorder. Such mice have recently been generated 50 and should provide a more definite answer whether loss of PHLPP1 expression contributes to the development and/or progression of CLL.
